Address:One Ledgemont Center
128 Spring Street
In Vivo summarizes the technologies of several recently founded companies: Ardais Corp., is creating information products from consolidating high-quality, reliable biological samples and related information for use in drug discovery and development. BeneCor Heart Systems was founded in September 1999 to develop and commercialize a totally implantable, permanent heart replacement device. Chronix Biomedical will focus on the diagnosis and management of chronic diseases by detecting what it calls "reshuffled genes," the detours the human genome map takes when confronted with viruses or other toxins. Founded in July 1999 by a group of former Columbia University physicians and scientists, MediData Solutions Inc. will offer new software and technology for managing clinical trials. Spiration is developing devices to treat pulmonary diseases, in particular chronic obstructive pulmonary disease (COPD), for which no cure exists.
Address:One Ledgemont Center
128 Spring Street
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.